Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.54 |
| ▸ | CTSD | P07339 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446300 | 0.89 | BACE1 (0.58) | BACE1CTSDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL445211 | 0.86 | BACE1 (0.73) | BACE1CTSDBACE2KCNH2 | |
| SCHEMBL447848 | 0.85 | BACE1 (0.59) | BACE1CTSDBACE2KCNH2 | |
| SCHEMBL446464 | 0.82 | BACE1 (0.53) | BACE1CTSDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL446041 | 0.82 | BACE1 (0.53) | BACE1CTSDBACE2 | |
| SCHEMBL15589528 | 0.78 | BACE1 (0.46) | BACE1CTSDBACE2KCNH2 | |
| SCHEMBL15589016 | 0.74 | BACE1 (0.77) | BACE1KCNH2 | |
| SCHEMBL447030 | 0.74 | BACE1 (0.49) | BACE1CTSDBACE2 | |
| SCHEMBL449162 | 0.70 | BACE1 (0.46) | BACE1CTSDBACE2 | |
| SCHEMBL445389 | 0.70 | BACE1 (0.65) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 427/4885NPC1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.